BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu Z, Luo W, Chen L, Zhuang Z, Yang D, Qian J, Khan ZA, Guan X, Wang Y, Li X, Liang G. Ang II (Angiotensin II)-Induced FGFR1 (Fibroblast Growth Factor Receptor 1) Activation in Tubular Epithelial Cells Promotes Hypertensive Kidney Fibrosis and Injury. Hypertension 2022;79:2028-41. [PMID: 35862110 DOI: 10.1161/HYPERTENSIONAHA.122.18657] [Reference Citation Analysis]
2 Guixé-Muntet S, Biquard L, Szabo G, Dufour JF, Tacke F, Francque S, Rautou PE, Gracia-Sancho J. Review article: vascular effects of PPARs in the context of NASH. Aliment Pharmacol Ther 2022;56:209-23. [PMID: 35661191 DOI: 10.1111/apt.17046] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Reference Citation Analysis]
4 Boyer-diaz Z, Aristu-zabalza P, Andrés-rozas M, Robert C, Ortega-ribera M, Fernández-iglesias A, Broqua P, Junien J, Wettstein G, Bosch J, Gracia-sancho J. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. Journal of Hepatology 2021;74:1188-99. [DOI: 10.1016/j.jhep.2020.11.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
5 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Sanz-garcía C, Fernández-iglesias A, Gracia-sancho J, Arráez-aybar LA, Nevzorova YA, Cubero FJ. The Space of Disse: The Liver Hub in Health and Disease. Livers 2021;1:3-26. [DOI: 10.3390/livers1010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers (Basel) 2020;12:E3748. [PMID: 33322158 DOI: 10.3390/cancers12123748] [Reference Citation Analysis]
8 Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia-Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. Nutrients 2020;12:E2627. [PMID: 32872239 DOI: 10.3390/nu12092627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Pietrosi G, Fernández-Iglesias A, Pampalone M, Ortega-Ribera M, Lozano JJ, García-Calderó H, Abad-Jordà L, Conaldi PG, Parolini O, Vizzini G, Luca A, Bosch J, Gracia-Sancho J. Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats. Liver Int 2020;40:2500-14. [PMID: 32996708 DOI: 10.1111/liv.14610] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]